NCT01634971

Brief Summary

Postoperative pancreatic fistula (POPF) and other surgical complications are common after pancreatoduodenectomy (PD) and POPF is a major complication. The drainage of pancreatic duct is important and a stent is usually placed in the operation, but it is still controversial whether the stent drainage is internal or external.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started May 2012

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 3, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 6, 2012

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

February 17, 2016

Status Verified

January 1, 2013

Enrollment Period

4.6 years

First QC Date

July 3, 2012

Last Update Submit

February 14, 2016

Conditions

Keywords

Postoperative pancreatic fistula(POPF);Postpancreatectomy hemorrhage(PPH);Delayed gastric emptying (DGE);Bile leakage after pancreatic surgery;Anastomotic leakage

Outcome Measures

Primary Outcomes (1)

  • the rate of Postoperative pancreatic fistula within 2 weeks after operation

    Postoperative pancreatic fistula (POPF) is defined as a drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase activity.

    within 2 weeks after operation

Secondary Outcomes (1)

  • the rate of postoperative Surgical Complications

    2 weeks after operation

Study Arms (2)

External Drainage of pancreatic duct

NO INTERVENTION

External Drainage of pancreatic duct was used in PD.

Internal Drainage of Pancreatic Duct

EXPERIMENTAL

the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.

Procedure: Internal Drainage of Pancreatic Duct after pancreatomy

Interventions

the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.

Internal Drainage of Pancreatic Duct

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age more than 18 years.
  • Received pancreatoduodenectomy.
  • Informed consent has been signed.

You may not qualify if:

  • Age less than 18 years
  • Emergency surgery
  • Past history of pancreatic surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China

RECRUITING

MeSH Terms

Conditions

GastroparesisAnastomotic Leak

Condition Hierarchy (Ancestors)

Stomach DiseasesGastrointestinal DiseasesDigestive System DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic Processes

Study Officials

  • Qiang WU, MD. Ph.D.

    Tianjin Medical University Cancer Institute and Hospital

    STUDY CHAIR

Central Study Contacts

Qiang WU, MD. Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 3, 2012

First Posted

July 6, 2012

Study Start

May 1, 2012

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

February 17, 2016

Record last verified: 2013-01

Locations